Trial Profile
A Single-Dose, Dose-Escalating Study Exploring the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Inhaled Treprostinil Sodium Using the Nebu-Tec OPTINEB Inhalation Device in Patients With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2014
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Proof of concept
- Sponsors Lung Biotechnology
- 25 Jun 2014 New trial record
- 23 Feb 2010